ANTIALLERSIN

StockNo	Product description
EB0280-446-02	ANTIALLERSIN AMPOULE 25 MG/1 ML (2.5%)
EB0280-446-14	ANTIALLERSIN AMPOULE 50 MG/1 ML (2.5%)

 

COMPOSITION:
Promethazine hydrochloride 25mg/1ml
50mg/2ml in one ampoule.

PHARMACOLOGICAL ACTION:
Antiallersin is similar in its chemical structure and partially in its pharmacological action to the neuroleptic Chlorazan. Its best manifested property is the strong antihistamine activity, coupled with its antiallergic action. Furthermore, it has a considerable effect on CNS; it has a strong sedative action, enhances the action of narcotics, sopofifies, spasmolytics and topical anesthetics, decreases body temperature, prevents and stops vomiting, copes with hiccup; it has a moderate peripheral and central chlinolytic action, and a pronounced adrenolytic action.

INDICATIONS:
Allergic skin diseases urticaria of different genesis, allergic dermatitis, eczema; drug allergy with skin manifestations.
Allergic diseases of the respiratory pathways: allergic rhinitis and sinusitis, spastic bronchitis and bronchial asthma, hay fever.
General allergic reaction: anaphylactic shock, serum sickness, angioneurotic edema, Quincke's edema.
Sea and air sickness, Meniere's disease, chorea, encephalitis in surgery as one of the components of the so-called "lytic cocktail", vomiting of various origin, in combination with spasmolytics in biliary and renal colic, for enhancement of the action of analgesics.

CONTRAINDICATIONS:
Due to its marked sedative (and slight soporific) effect, it must not be prescribed to individuals whose work requires sharp attention (drivers, engine drivers, etc.) or to persons with alcohol intoxication.

PRECAUTIONS:
To avoid the irritating effect on mucosae and skin, caution should be exercised when administering the drug (proper ventilation, rubber gloves).

DRUG INTERACTIONS:
Promethazine potentiates the sedative effect of the agents inhibiting the CNS (alcohol, general anesthetics, analgesics), the anticholinergic action of cholinolytics and tricyclic antidepressants; its vasopressor effect can be intensified by MAO-inhibitors.

DOSAGE AND ADMINISTRATION:
Parenterally - 0.025 intramuscularly or intravenously as a component of the "lytic cocktail" - 0.05.

MEDICINAL FORM AND PACKAGE:
Packages with 10, 50 and 100 ampoules of 25 mg/l ml and of 50 mg/2 ml (2.5 %).

STORAGE:
At a moderate temperature (15-30° C) in a place protected from direct sunlight.

EXPIRY:
5 (five) years.